MiR-543/Numb Promotes Proliferation, Metastasis, and Stem-like Cell Traits of Prostate Cancer Cells
Overview
Authors
Affiliations
MiR-543 and Numb are associated with various malignancies, including prostate cancer (PCa). However, whether miR-543 regulates Numb in PCa development remains unclear. In this study, we identified Numb as a direct target of miR-543. The role of miR-543 was examined both in vitro and in vivo. The in vivo effects of miR-543 were investigated using tumor transplantation experiments and a lung metastasis model. The in vitro effects of miR-543 on proliferation, migration, invasion, and cancer stem-like cell (CSC)-associated properties were also examined. The binding sites of Numb were predicted using bioinformatics tools and confirmed by luciferase and rescue assays. QRT-PCR and western blot analyses were used to detect target expression levels. Expression levels of both miR-543 and Numb were manipulated in CD44+ and CD44-PCa cells followed by a series of functional assays. The results demonstrated that miR-543 promoted PCa growth and metastasis both in vivo and in vitro. Luciferase reporter assays, qRT-PCR, and western blot analyses revealed Numb as a direct target of miR-543. The function of miR-543 was abolished by Numb, as shown in rescue experiments. Moreover, miR-543 was verified to promote CSC properties, whereas Numb elicited the opposite effects. MiR-543 also influenced the expression of several stem-like factors, including Dll4, NF-κB, c-myc, and Oct-4, and the Numb/p53 signaling pathway. Taken together, these results demonstrate that miR-543 plays an oncogenic role by negatively controlling Numb, revealing the existence of an miR-543/Numb/p53 regulatory pathway in PCa tumorigenesis and development.
Zhang Y, Yang H, Liu W, Song Q, Li Y, Zhang J Medicine (Baltimore). 2023; 102(35):e34717.
PMID: 37657045 PMC: 10476719. DOI: 10.1097/MD.0000000000034717.
The Molecular Biology of Prostate Cancer Stem Cells: From the Past to the Future.
Zhou Y, Li T, Jia M, Dai R, Wang R Int J Mol Sci. 2023; 24(8).
PMID: 37108647 PMC: 10140972. DOI: 10.3390/ijms24087482.
State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer.
Ramesh S, Selvakumar P, Ameer M, Lian S, Abdullah Alzarooni A, Ojha S Front Oncol. 2023; 13:1059441.
PMID: 36969009 PMC: 10035756. DOI: 10.3389/fonc.2023.1059441.
Rincon-Riveros A, Rodriguez J, Villegas V, Lopez-Kleine L Noncoding RNA. 2022; 8(3).
PMID: 35645340 PMC: 9149928. DOI: 10.3390/ncrna8030033.
Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer.
Ganini C, Amelio I, Bertolo R, Candi E, Cappello A, Cipriani C Discov Oncol. 2022; 12(1):45.
PMID: 35201488 PMC: 8777499. DOI: 10.1007/s12672-021-00440-7.